{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:48:08Z","timestamp":1794473288488,"version":"4.9.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41375-025-02548-z","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T06:55:36Z","timestamp":1741157736000},"page":"1056-1057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Living, not just surviving, with chronic myeloid leukemia \u2013 quality of life to the front of the line"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-7168","authenticated-orcid":false,"given":"Jeffrey H.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"2548_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/cells10010117","volume":"10","author":"VR Minciacchi","year":"2021","unstructured":"Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past, present and future. Cells. 2021;10:117. https:\/\/doi.org\/10.3390\/cells10010117.","journal-title":"Cells"},{"key":"2548_CR2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866.","journal-title":"J Clin Oncol"},{"key":"2548_CR3","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99:2191\u2013212. https:\/\/doi.org\/10.1002\/ajh.27443.","journal-title":"Am J Hematol"},{"key":"2548_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11899-016-0306-5","volume":"11","author":"KE Flynn","year":"2016","unstructured":"Flynn KE, Atallah E. Quality of life and long-term therapy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11:80\u20135. https:\/\/doi.org\/10.1007\/s11899-016-0306-5.","journal-title":"Curr Hematol Malig Rep."},{"key":"2548_CR5","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.21037\/apm-22-158","volume":"11","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Li Z, Hou Y, Dang H, Chen J, Liang L, et al. Chronic disease management practices and factors associated with health-related quality-of-life for persons with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Ann Palliat Med. 2022;11:1336\u201350. https:\/\/doi.org\/10.21037\/apm-22-158.","journal-title":"Ann Palliat Med"},{"key":"2548_CR6","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.blre.2022.100968","volume":"56","author":"JH Lipton","year":"2022","unstructured":"Lipton JH, Br\u00fcmmendorf TH, Gambacorti-Passerini C, Garcia-Guti\u00e9rrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022;56:100968. https:\/\/doi.org\/10.1016\/j.blre.2022.100968.","journal-title":"Blood Rev"},{"key":"2548_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00432-021-03624-4","volume":"148","author":"L Yu","year":"2022","unstructured":"Yu L, Wang H, Gale RP, Qin Y, Lai Y, Shi H, et al. Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia. Cancer Res Clin Oncol. 2022;148:449\u201359. https:\/\/doi.org\/10.1007\/s00432-021-03624-4.","journal-title":"Cancer Res Clin Oncol"},{"key":"2548_CR8","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s00432-017-2517-0","volume":"143","author":"Q Jiang","year":"2017","unstructured":"Jiang Q, Wang H, Yu L, Gale RP. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2017;143:2619\u201330. https:\/\/doi.org\/10.1007\/s00432-017-2517-0.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2548_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.clml.2023.11.011","volume":"24","author":"E Abruzzese","year":"2024","unstructured":"Abruzzese E, Trawinska MM, De Fabritiis P, Bernardi S. SOHO state of the art updates and next questions: chronic myeloid leukemia and pregnancy: \u201cPer Aspera Ad Astra\u201d. Clin Lymphoma Myeloma Leuk. 2024;24:214\u201323. https:\/\/doi.org\/10.1016\/j.clml.2023.11.011.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2548_CR10","doi-asserted-by":"publisher","unstructured":"Chen EY, Dahl\u00e9n T, Stenke L, Bj\u00f6rkholm M, Hao S, Dickman PW, et al (2024) Loss in overall and quality-adjusted life expectancy for patients with chronic-phase chronic myeloid leukemia. Eur J Haematol. https:\/\/doi.org\/10.1111\/ejh.14328.","DOI":"10.1111\/ejh.14328"},{"key":"2548_CR11","doi-asserted-by":"publisher","first-page":"e849","DOI":"10.1016\/S2352-3026(23)00173-4","volume":"10","author":"Y Smit","year":"2023","unstructured":"Smit Y, Metsemakers SJJPM, Janssen JJWM, Posthuma EFM, Walraven I, Hermens RPMG, et al. Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures. Lancet Haematol. 2023;10:e849\u2013e859. https:\/\/doi.org\/10.1016\/S2352-3026(23)00173-4.","journal-title":"Lancet Haematol"},{"key":"2548_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11899-021-00656-y","volume":"16","author":"KL Schoenbeck","year":"2021","unstructured":"Schoenbeck KL, Flynn KE. Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions. Curr Hematol Malig Rep. 2021;16:491\u20139. https:\/\/doi.org\/10.1007\/s11899-021-00656-y.","journal-title":"Curr Hematol Malig Rep"},{"key":"2548_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jnci\/djab184","volume":"114","author":"KL Schoenbeck","year":"2022","unstructured":"Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, et al. Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Cancer Inst. 2022;114:160\u20134. https:\/\/doi.org\/10.1093\/jnci\/djab184.","journal-title":"J Natl Cancer Inst"},{"key":"2548_CR14","doi-asserted-by":"publisher","first-page":"204062072312160","DOI":"10.1177\/20406207231216077","volume":"14","author":"D Russo","year":"2023","unstructured":"Russo D, Malagola M, Polverelli N, Farina M, Re F, Bernardi S. Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient. Ther Adv Hematol. 2023;14:20406207231216077. https:\/\/doi.org\/10.1177\/20406207231216077.","journal-title":"Ther Adv Hematol"},{"key":"2548_CR15","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2217\/fon-2022-1267","volume":"19","author":"J Clements","year":"2023","unstructured":"Clements J, Fleischman A, Lerner V, Ruiz C. The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist. Future Oncol. 2023;19:1197\u2013208. https:\/\/doi.org\/10.2217\/fon-2022-1267.","journal-title":"Future Oncol"},{"key":"2548_CR16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11899-019-00546-4","volume":"14","author":"F Rabian","year":"2019","unstructured":"Rabian F, Lengline E, Rea D. Towards a personalized treatment of patients with chronic myeloid leukemia. Curr Hematol Malig Rep. 2019;14:492\u2013500. https:\/\/doi.org\/10.1007\/s11899-019-00546-4.","journal-title":"Curr Hematol Malig Rep."},{"key":"2548_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11899-019-00524-w","volume":"14","author":"M Copland","year":"2019","unstructured":"Copland M. Is There a role for dose modification of TKI therapy in CML? Curr Hematol Malig Rep. 2019;14:337\u201345. https:\/\/doi.org\/10.1007\/s11899-019-00524-w.","journal-title":"Curr Hematol Malig Rep."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02548-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02548-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02548-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:46:27Z","timestamp":1746531987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02548-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2548"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02548-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}